Shots: On Apr 02, 2020, EMA’s CHMP has recommended Gilead’s Remdesivir to be used for treating COVID-19 in compassionate use programmes in the EU Compassionate use programmes are intended to provide patients access to therapies that are under development and have not yet received a marketing authorization. The CHMP encourages Gilead to make remdesivir available […]Read More
Shots: The IDE compassionate use and continued access studies involve assessing of Spray-On Skin Cells prepared using the RECELL system + meshed autografts in 107 pediatric patients with deep burn injuries The interim analyses results: healing within 4wks. (98%); patients with >50% TBSA achieve the same rate of healing as patients with ≤50% TBSA; donor […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
